EXPLORE!

Medical Voice 16th December 2019

  771 Views

Dr KK Aggarwal    16 December 2019

Heart Care Foundation of India (HCFI) trains over 500 children from SD Vidya School in cardiopulmonary resuscitation (CPR) and other health aspects | Sangyan News

Children were also made aware of the importance of taking care of their parents health

New Delhi, 13th December 2019: The Heart Care Foundation of India (HCFI), a leading national NGO, recently organized an event to create awareness among school students on various health-related aspects. Over 500 students from SD Vidya School, Noida were trained on hygiene, pollution, CPR and how to save someone from choking.

Renowned industrialist Mr Brij Soni was one of the guests at the event. HCFI regularly conducts such awareness initiatives in various schools since they can be the hotbed for change healthy change. The organization believes that children at this age can be shapedinto better individuals, both in body and mind. ....read more

Simple Aspirin as Good as Newer drugs for aborting or preventing acute migraine attack

Old aged aspirin is as effective for acute treatment and prevention of recurrent migraine attacks as more expensive medications.

A review of randomized trials suggests that high-dose aspirin is effective and safe for acute migraine and that low-dose aspirin may help prevent migraine attacks. The study was published online October 12 in the American Journal of Medicine.

Migraine affects an estimated 14% of the general population and is more prevalent in women (18%) than men (9%). About 90% of migraine patients report moderate to severe pain associated with their attacks. More than 50% report severe impairment, which often results in reduced work and school productivity. ....read more

Healthcare News Monitor

 

AT & IT China 2020 to showcase intelligent pharma solutions

Bio Spectrum 

AT & IT China 2020, organized by Informa Markets and China Chamber of Commerce for Import & Export of Medicines & Health Products and co-organized by Shanghai Sinoexpo Informa Markets International Exhibition Co., Ltd., to take place at the Shanghai New International Expo Centre on June 22-24, 2020 together with CPhI & P-MEC China 2020, will focus on automatic production, information system layout, network security, and the new trend of safety and lean manufacturing of the pharmaceutical industry. Chinas pharmaceutical industry has rapidly developed in the past decade with the gross output value increasing from RMB 667.9 billion to nearly RMB 3 trillion in 2017. In recent years, Chinese pharmaceutical industry is entering a brand-new era that focuses on quality and innovation with new policies for the implementation of generic drug consistency evaluation, acceleration of pharmaceutical product review and approval, etc. Improvement of pharmaceutical equipment quality and stability and optimization of the pharmaceutical industrys automation and information levels has become key factors for pharmaceutical enterprises to achieve quality assurance and improve innovation abilities. As a result, to meet the digital production transformation of the fast-growing pharmaceutical industry, more and more equipment suppliers have thrown themselves into intelligent equipment upgrading.

Aurobindo Pharma arm recalls 59k vials of antipsychotic Fluphenazine Decanoate injection from US

Medical Dialogues 

Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59,500 vials of the injection on account of “Discoloration; hazy solution found in one vial instead of a clear solution,” the US Heath Regulator (USFDA) said in its latest Enforcement Report. Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59.5 thousand vials of antipsychotic Fluphenazine Decanoate injection USP 125mg/5mL, (5 mL multiple dose vial) from the US market, the USFDA said. New Delhi: Aurobindo Pharma arm AuroMedics Pharma LLC is recalling 59,500 vials of the injection on account of “Discoloration; hazy solution found in one vial instead of a clear solution,” the US Heath Regulator (USFDA) said in its latest Enforcement Report. The product was distributed to major wholesalers/distributors who may have further distributed the product throughout the US, it added. The voluntary ongoing recall is a class II recall, the United States Food and Drug Administration (USFDA) said. As per the regulator, class II recall is initiated in a “situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote”.

Roches Tecentriq cocktail scores trial success in melanoma

ET Healthworld- Reuters

A late-stage clinical trial has shown therapy combining Roches immunotherapy Tecentriq with two of its other drugs helped people with a form of advanced melanoma, the Swiss drugmaker said on Friday. The study met its primary aim of showing progression-free survival in patients with previously untreated BRAF V600 mutation-positive advanced melanoma, Roche said. Adding Tecentriq, a monoclonal antibody, to Cotellic and Zelboraf helped reduce the risk of disease worsening or death compared to administering a placebo plus Cotellic and Zelboraf. "By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma," said Levi Garraway, Roches chief medical officer and head of product development. Roche has an extensive clinical trial development programme for Tecentriq, with more than 50 studies for use in fighting lung, kidney, skin, breast, colorectal, prostate, ovarian, bladder, blood, liver and head and neck cancers.

CVS to increase genetic testing for some Aetna cancer patients

ET Healthworld- Reuters

CVS Health Corp said on Thursday it will make it easier for patients with advanced cancer enrolled in some Aetna insurance plans to receive broad genetic gene sequencing tests that can help identify the best drug or treatment for them. CVS has been running an oncology program in 12 states in which patients prescribed treatment regimens that follow National Comprehensive Cancer Network guidelines automatically receive prior authorization approval, speeding the time to starting their treatment. It will now add easier access to broad-panel gene sequencing tests to that program for patients in its at-risk Aetna plans, Alan Lotvin, CVS chief transformation officer said in an interview. In at-risk insurance plans CVS, which acquired Aetna last year for $69 billion, takes on the risk of higher member costs. The genetic sequencing of tumors would be available for patients with late-stage cancer or whose cancers progress after prior treatments, representing about 30 percent of patients, Lotvin said. The testing will be done by Tempus, a next-generation gene sequencing company in Chicago.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.